Rheumatology Network's Top 5: September 10, 2022

Published on: 

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending September 10, 2022.

Ustekinumab Quickly, Effectively Treats Patients with Active PsA

In the prospective, non-interventional SUSTAIN study, patients with active psoriatic arthritis received ustekinumab for 3 years in routine clinical care.

Rheumatology Month in Review: August 2022

Rheumatology Network's month in review spotlights the most popular content from the past month.

Litifilimab Superior to Placebo in Patients with Cutaneous Lupus Erythematosus

“Whether treatment with litifilimab, a humanized monoclonal antibody against BDCA2, would be efficacious in reducing disease activity in patients with cutaneous lupus erythematosus has not been extensively studied.”

Anxiety, Depression Highly Prevalent in Patients with Lupus Nephritis

"Lupus nephritis (LN) patients might suffer from mental disorders which further prolong the LN treatment duration and affect patients' quality of life.”

Kinesiophobia Negatively Impacts Functional Task Performance in JIA

“Kinesiophobia plays a major role in the onset, persistence, and exacerbation of chronic disability in a variety of musculoskeletal disorders."